From ClinicalTrials.gov
GLP-1 clinical trial results
290 Phase 3 trials with posted results, 146 of them named. Each page shows the results and side effects arm by arm, as the registry posts them. The newest update at source is Nov 4, 2026.
Largest first
Dulaglutide trials with results
26 trials, 38,927 participants.
| Trial | Medication | People | Primary result |
|---|---|---|---|
| SURPASS-CVOTA Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes | Dulaglutide | 13,299 | Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke] (participants), From randomization (week 0) up to week 259. Tirzepatide (MTD): 801; 1.5 mg Dulaglutide: 862. |
| REWINDResearching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) | Dulaglutide | 9,901 | Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (Participants), From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years). Placebo: 663; Dulaglutide: 594. |
| AWARD-11A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes | Dulaglutide | 1,842 | Change in Hemoglobin A1c (HbA1c) From Baseline (Percentage of HbA1c), Baseline, Week 36. Dulaglutide 1.5 mg: -1.53; Dulaglutide 3 mg: -1.71; Dulaglutide 4.5 mg: -1.87. |
| NCT00734474A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin | Dulaglutide | 1,202 | Glycosylated Hemoglobin (HbA1c) Change From Baseline (percentage of HbA1c), Baseline, 52 weeks. 1.5 mg LY2189265: -1.10; 0.75 mg LY2189265: -0.87; Sitagliptin: -0.39. |
| SUSTAIN 7Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes. | Dulaglutide | 1,201 | Change in HbA1c (percentage of HbA1c), Week 0, week 40. Semaglutide 0.5 mg: -1.51; Semaglutide 1.0 mg: -1.78; Dulaglutide 0.75 mg: -1.11; Dulaglutide 1.5 mg: -1.37. |
| AWARD-1A Study in Participants With Type 2 Diabetes Mellitus | Dulaglutide | 978 | Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c) (percentage of glycosylated hemoglobin), Baseline, 26 weeks. 1.5 mg LY2189265: -1.51; 0.75 mg LY2189265: -1.30; Exenatide: -0.99; Placebo: -0.46. |
| AMPLITUDE-DEfficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin | Dulaglutide | 908 | Change From Baseline to Week 56 in HbA1c (percentage of HbA1c), Baseline to Week 56. Efpeglenatide 4 mg: -1.12; Efpeglenatide 6 mg: -1.17; Dulaglutide 1.5 mg: -1.09. |
| NCT01191268A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4) | Dulaglutide | 884 | Change From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c) (percentage of glycosylated hemoglobin), Baseline, 26 weeks. 1.5 mg LY2189265: -1.64; 0.75 mg LY2189265: -1.59; Insulin Glargine: -1.41. |
| AWARD-2A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2) | Dulaglutide | 810 | Change From Baseline to 52 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c) (percentage of glycosylated hemoglobin), Baseline, 52 weeks. LY2189265 1.5 mg: -1.08; LY2189265 0.75 mg: -0.76; Insulin Glargine: -0.63. |
| NCT01126580A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3) | Dulaglutide | 807 | Change From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c) (percentage of glycosylated hemoglobin), Baseline, 26 weeks. 1.5 mg LY2189265: -0.78; 0.75 mg LY2189265: -0.71; Metformin: -0.56. |
| AWARD-CHN2A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus | Dulaglutide | 774 | Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks (percentage of HbA1c), Baseline, 26 Weeks. 1.5 mg Dulaglutide: -1.73; 0.75 mg Dulaglutide: -1.33; Insulin Glargine: -1.16. |
| AWARD-CHN1A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus | Dulaglutide | 737 | Change From Baseline in HbA1c at 26 Weeks (percentage of HbA1c), Baseline, 26 Weeks. 1.5 mg Dulaglutide: -1.48; 0.75 mg Dulaglutide: -1.22; Glimepiride: -0.92. |
| SURPASS J-monoA Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes | Dulaglutide | 636 | Change From Baseline in Hemoglobin A1c (HbA1c) (percentage of HbA1c), Baseline, Week 52. 5 mg Tirzepatide: -2.37; 10 mg Tirzepatide: -2.55; 15 mg Tirzepatide: -2.82; 0.75 mg Dulaglutide: -1.29. |
| AWARD-6A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes | Dulaglutide | 599 | Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c) (percentage of glycosylated hemoglobin), Baseline, 26 Weeks. 1.5 mg LY2189265: -1.42; 1.8 mg Liraglutide: -1.36. |
| AWARD-JPNA Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes | Dulaglutide | 591 | Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26 (Percentage of HbA1c), Baseline, Week 26. Dulaglutide 1.5 mg: -1.53; Dulaglutide 0.75 mg: -1.25. |
| AWARD-7A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD) | Dulaglutide | 577 | Change From Baseline in Hemoglobin A1c (HbA1c) (percentage of HbA1c), Baseline, 26 Weeks. Insulin Glargine: -1.13; Dulaglutide 0.75 mg: -1.12; Dulaglutide 1.5 mg: -1.19. |
| NCT01558271A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus | Dulaglutide | 492 | Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks (percentage of HbA1c), Baseline, 26 weeks. LY2189265: -1.43; Placebo: 0.14; Liraglutide: -1.33. |
| PIONEER 10Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes | Dulaglutide | 458 | Number of Treatment-emergent Adverse Events (TEAEs) (Events), Weeks 0-57. Oral Semaglutide 3 mg: 330; Oral Semaglutide 7 mg: 350; Oral Semaglutide 14 mg: 324; Dulaglutide 0.75 mg: 178. |
| AWARD-10A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus | Dulaglutide | 424 | Change From Baseline in Hemoglobin A1c (HbA1c) at 24 Weeks (Treatment-regimen Estimand) (percentage of HbA1c), Baseline, Week 24. 1.5 mg Dulaglutide: -1.34; 0.75 mg Dulaglutide: -1.21; Placebo: -0.54. |
| NCT01468181A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus | Dulaglutide | 394 | Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) (percentage of participants), Baseline through 52 Weeks. LY2189265 + SU: 85.5; LY2189265 + BG: 83.6; LY2189265 + a-GI: 70.8; LY2189265 + TZD: 80.3; LY2189265 + Glinides: 73.2. |
| NCT01584232A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus | Dulaglutide | 361 | Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks (percentage of HbA1c), Baseline, 26 weeks. LY2189265 + OAM: -1.44; Insulin Glargine + OAM: -0.90. |
| AWARD-9A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes | Dulaglutide | 300 | Change From Baseline to 28 Weeks in Hemoglobin A1c (HbA1c) (percentage of change), Baseline, 28 Weeks. Dulaglutide + Insulin Glargine: -1.44; Placebo + Insulin Glargine: -0.67. |
| AWARD-8Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8) | Dulaglutide | 300 | Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at 24 Weeks (percent change of HbA1c), Baseline, 24 Weeks. Dulaglutide: -1.38; Placebo: -0.11. |
| AWARD-CHN3A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes | Dulaglutide | 291 | Change From Baseline in Hemoglobin A1c (HbA1c) (Percentage of HbA1c), Baseline, Week 28. 1.5 mg Dulaglutide: -2.03; Placebo: -1.08. |
| AWARD-PEDSA Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes | Dulaglutide | 154 | Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses) at Week 26 (percentage of HbA1C), Baseline, Week 26. Placebo: 0.5; Pooled Dulaglutide: -0.7. |
| GLIMPEffects of GLP1-RA on Ectopic Fat Deposition in Chronic Kidney Disease | Dulaglutide | 7 | See the trial's page: several measures or groups. |
Updated automatically
What just changed in the registry
- TrialNew Semaglutide study registered: A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity
- TrialSemaglutide study now completed (was unknown): The Effect of Different Diets on Arterial Stiffness in Obese Patients on Semaglutide
- TrialSemaglutide study now recruiting (was not yet recruiting): Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes
- TrialExenatide study now completed (was active, not recruiting): Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol
- TrialTirzepatide study now recruiting (was not yet recruiting): AI-Assisted Lifestyle Intervention Versus Tirzepatide for Obesity and Newly Diagnosed Type 2 Diabetes
- TrialTirzepatide study now recruiting (was not yet recruiting): A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
- TrialNew Liraglutide study registered: The Effect of Liraglutide on Body Weight, Body Composition, Ectopic Lipid Accumulation and Insulin Sensitivity in Subjects With Overweight or Obesity Without Diabetes
- TrialNew MariTide study registered: Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA)
Written from each source's own record as it changes. Every change on GLPcompare
GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.